Moderna’s seasonal influenza vaccine candidate, mRNA-1010, demonstrated a 26.6% relative vaccine efficacy over a licensed standard-dose seasonal influenza vaccine in adults aged 50 and older across an extensive multinational Phase 3 trial. The vaccine showed consistent protection against all targeted influenza strains, including A/H1N1, A/H3N2, and B lineages. Side effects were generally mild and comparable to existing vaccines. The positive data redevelopment positions Moderna to seek FDA approval potentially as early as the 2026-2027 flu season, with future prospects including combination formulations targeting both COVID-19 and influenza.